Gabrail Cancer and Research Center

Canton, Ohio 44718

2 studies enrolling now · 11 studies all time

What they study most

Adjuvant, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Squamous Non-Small Cell Lung Carcinoma, Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, Colorectal Cancer, EGFR, Early Stage Lung Cancer, Exon 20, Hepatocellular Carcinoma

Studies at this site

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer — Recruiting now
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
A Study of ASP1012 in Adults With Solid Tumors — Stopped early
Study of PYX-106 in Solid Tumors — Running, not enrolling
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors — Stopped early
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation — Completed
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma — Paused
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours — Stopped early
Study of LM-102 in Subjects in Advanced Tumors — Stopped early